Abstract
Immune checkpoint inhibitor (ICI) therapies have emerged as a potent option for the treatment of non-small cell lung cancer (NSCLC). ICI therapies fight the tumour through an up-regulation of the immune system and achieve a higher efficacy compared to traditional platinum-based chemotherapies. Major downsides of ICI-treatments are the varying response rates and sometimes even severe immune related adverse events (irAE).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
